Skip to content

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Christopher Paul Cannon, Michael A. Blazing, Robert Patrick Giugliano, Amy McCagg, Jennifer A. White, Pierre Théroux, Harald Darius, Basil S. Lewis, Ton Oude Ophuis, J. Wouter Jukema, Gaetano Maria De Ferrari, Witold Rużyłło, Paul De Lucca, Erin Ann Bohula, Stephen D. Wiviott, Andrew M. Tershakovec, Eugene Braunwald, Robert M. Califf

New England Journal of Medicine · 2015 · 4,600 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Théroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., Ferrari, G. M. D., Rużyłło, W., Lucca, P. D., Im, K., Bohula, E. A., Reist, C., Wiviott, S. D., Tershakovec, A. M., Musliner, T. A., … Califf, R. M. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine, 372(25), 2387–2397. https://doi.org/10.1056/nejmoa1410489

In text: (Cannon et al., 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P=0.016). Rates of prespecified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.).

  1. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge1972
  2. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)1993
  3. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study2004
  4. Diagnosis and Management of the Metabolic Syndrome2005
  5. Prediction of Coronary Heart Disease Using Risk Factor Categories1998

Metadata from OpenAlex (CC0). Citations are generated from the published record.